Last reviewed · How we verify
NCT04969718: SEPAK
Suicide Prevention by Empowering Adolescents in Pakistan (SEPAK)
NA trial testing LEADS Plus educational posters in Self-harm in 1,350 participants. Completed in 30 August 2022.
28 April 2022
Quick facts
| Lead sponsor | Pakistan Institute of Living and Learning |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 1,350 |
| Start date | 1 July 2021 |
| Primary completion | 28 April 2022 |
| Estimated completion | 30 August 2022 |
| Sites | 8 locations across Pakistan |
Drugs / interventions tested
- LEADS Plus educational posters
- Question, Persuade, and Refer (Teachers) Plus educational posters
- Screening by Professionals programme plus educational posters
- educational posters
- Question, Persuade, and Refer (Parents) Plus educational posters
Conditions studied
- Self-harm — all drugs for Self-harm →
Sponsor
Pakistan Institute of Living and Learning
Who can join
Adults 12 to 17, any sex, with Self-harm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Self-harm is now seen as an epidemic affecting young people across the world and particularly in low and middle-income countries (LMIC) such as Pakistan. Young people in Pakistan often come across many troubles such as mental health and family problems, stress at school and social and economic inequalities. A youth suicide prevention programme is needed in Pakistan. Such programme will be based on secondary schools (where most young people are) and will support schools to work together with many public agencies to tackle the full range of troubles that young people face. Our main research aim is to work together with multiple stakeholders to culturally adapt and test the feasibility of three SEPAK interventions to prevent suicide among students in secondary schools in Pakistan (aged 12 to 17 years).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prevention of self-harm and suicide in young people up to the age of 25 in education settings.
Sharma V, Marshall D, Fortune S, Prescott AE, et al · · 2024 · cited 5× · PMID 39704320 · DOI 10.1002/14651858.cd013844.pub2
Verify or expand the search:
- PubMed search for NCT04969718
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Self-harm
Currently open trials in the same condition.
- NCT06315075 — Dialectical Behavior Therapy for Adolescents With Self-harm and Suicidal Behavior- an Open Trial · NA · recruiting
- NCT06099561 — Intractable Self-harm-What Support is Effective? · recruiting
- NCT06345053 — Presence of PTSD and Emotion Dysregulation Among Inpatients With Substance Use Disorder · NA · recruiting
- NCT06406972 — Brief Admission by Self-referral for Individuals With Self-harm: Effects on Compulsory Care · recruiting
- NCT06424509 — Effects of Psychiatric Admissions on Self-harm and Suicide in People With Borderline Personality Disorder · recruiting
Other Pakistan Institute of Living and Learning trials
Trials by the same sponsor.
- NCT07015944 — Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan · NA · recruiting
- NCT06442007 — Universally Delivered Interventions for Young People · NA · not yet recruiting
- NCT07188597 — Culturally Adapted Cognitive Behavior Therapy for Individuals At Risk of First Episode Psychosis · NA · recruiting
- NCT03974620 — Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early Schizophrenia · NA · not yet recruiting
- NCT05933850 — Culturally Adapted Strong Families Programme for Families Living in Gilgit Baltistan, Pakistan · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04969718 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pakistan Institute of Living and Learning
- Last refreshed: 3 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04969718.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing